Khosrow Kashfi to Cyclooxygenase Inhibitors
This is a "connection" page, showing publications Khosrow Kashfi has written about Cyclooxygenase Inhibitors.
Connection Strength
1.725
-
Vannini F, Chattopadhyay M, Kodela R, Rao PPN, Kashfi K. Positional isomerism markedly affects the growth inhibition of colon cancer cells by NOSH-aspirin: COX inhibition and modeling. Redox Biol. 2015 Dec; 6:318-325.
Score: 0.471
-
Kodela R, Chattopadhyay M, Goswami S, Gan ZY, Rao PP, Nia KV, Vel?zquez-Mart?nez CA, Kashfi K. Positional isomers of aspirin are equally potent in inhibiting colon cancer cell growth: differences in mode of cyclooxygenase inhibition. J Pharmacol Exp Ther. 2013 Apr; 345(1):85-94.
Score: 0.394
-
Chattopadhyay M, Kodela R, Olson KR, Kashfi K. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model. Biochem Biophys Res Commun. 2012 Mar 16; 419(3):523-8.
Score: 0.370
-
Kashfi K, Rigas B. Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention. Biochem Pharmacol. 2005 Oct 01; 70(7):969-86.
Score: 0.238
-
Rigas B, Kashfi K. Cancer prevention: a new era beyond cyclooxygenase-2. J Pharmacol Exp Ther. 2005 Jul; 314(1):1-8.
Score: 0.229
-
Jain S, Tran S, El Gendy MA, Kashfi K, Jurasz P, Vel?zquez-Mart?nez CA. Nitric oxide release is not required to decrease the ulcerogenic profile of nonsteroidal anti-inflammatory drugs. J Med Chem. 2012 Jan 26; 55(2):688-96.
Score: 0.023